.jpg)
Vancouver, British Columbia, April 25, 2023 – Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, today announced upcoming event appearances and media coverage for Spring 2023.
EVENTS
-Filament CEO and Co-Founder Benjamin Lightburn has been invited to speak at MAPS Psychedelic Science Conference in Denver. Mr. Lightburn will participate in a panel entitled"The Future of Psychedelic Manufacturing" on Friday, June 23.
-Filament will also exhibit in the conference hall at booth #310.
-Mr. Lightburn will also speak at the PsychedelicTherapeutics and Drug Development Conference in San Francisco on May 15, with a presentation titled “The Natural Advantage: A Novel Approach to Approval.”
MEDIA
-On Wednesday, April 26, at 8:10 a.m. ET, Mr. Lightburn will appear on CTV’s Your Morning to discuss the Company’s recent development of GMP MDMA capsules.
-On Saturday, April 15, Filament was featured in The Globe & Mail, highlighting the recent development of pharmaceutical grade MDMA. Click here to read the article.
-On Monday, April 17, Mr. Lightburn spoke to CKNW Global News Radio about Filament’s efforts to improve access to MDMA for mental health treatment. Click here to listen.
VIRTUAL INVESTOR UPDATE
-On Thursday, May 18, at 11:00 a.m. PT / 2:00 p.m. ET, Filament will host a virtual update for shareholders and investors.
-Filament’s executive team will discuss recent progress and plans for the future, followed by a live question and answer period.
-Contact Anna Cordon at anna@filament.health to RSVP.
ABOUT FILAMENT HEALTH (OTCQB:FLHLF) (NEO:FH) (FSE:7QS)
Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament’s platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines. We are paving the way with the first-ever natural psychedelic drug candidates.
Learn more at www.filament.health and on Twitter,Instagram and LinkedIn.
MEDIA RELATIONS
Anna Cordon, Director of Communications
778.245.9067
anna@filament.health
INVESTOR RELATIONS
ir@filament.health
FORWARD LOOKING INFORMATION
Certain statements and information contained herein may constitute “forward-looking statements” and “forward-looking information,” respectively, under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as, “expect”,“anticipate”, “continue”, “estimate”, “may”, “will”, “should”, “believe”,“intends”, “forecast”, “plans”, “guidance” and similar expressions are intended to identify forward-looking statements or information. Forward-looking statements herein include, but are not limited to, statements regarding the benefits of the agreement between the Companies and the commercialization ofFilament’s natural psilocybin drug candidate, PEX010 (25 mg). There are numerous risks and uncertainties that could cause actual results and theCompanies’ plans and objectives to differ materially from those expressed in the forward-looking information. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice.. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. TheCompanies will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.
